Navigation Links
Helix BioPharma Announces Q1 2009 Financial Results
Date:12/11/2008

AURORA, Ontario, Dec. 11 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") today announced financial results for the first quarter of fiscal 2009, ended October 31, 2008.

RECENT HIGHLIGHTS

  • On October 2, 2008, the Company closed a private placement for gross proceeds of CDN$11.4 million.

  • Dr. Chao presented L-DOS47's mechanism of action at the Second Conference of Lung Cancer in Warsaw, Poland.

  • Helix filed a Form 20-F registration statement with the U.S. Securities and Exchange Commission.

Results from Operations

Three month period ended October 31, 2008 compared to the same period in the previous year

Loss for the period

During the first quarter of fiscal 2009, the Company recorded a loss of $2,321,000 or $0.05 per common share, resulting in a higher loss of $677,000 when compared to the first quarter of fiscal 2008. The Company recorded a loss of $1,644,000, or $0.05 per common share in the first quarter of fiscal 2008.

Revenues

Revenues in the first quarter of fiscal 2009 totaled $1,119,000 (2008 - $885,000), resulting in an increase of $234,000 or 26.4% when compared to the first quarter of fiscal 2008.

Product Revenue

Product revenues totaled $921,000 in the first quarter of fiscal 2009 and represent 82.3% of total revenues. When compared to the first quarter of fiscal 2008, product revenues increased by $167,000 or 22.1% and are primarily driven by higher Orthovisc(R) product sales.

License Fees and Royalty Revenue

License fees and royalties totaled $198,000 in the first quarter of fiscal 2009 and represent 17.7% of revenues.
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 2013 was ... Scottsdale’s Brain State Technologies®. They saw continued independent research ... Center who were awarded a $1 million grant from ... in “Brain and Behavior” a peer reviewed journal, Amy ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... at the University of Central Florida have developed a ... more sensitive tool to detect pathogens associated with inflammatory ... nanoparticle-based technique also may be used for detection of ... they hide deep in human tissue and are able ...
... 2012 Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company ... offer shares of its common stock and warrants to purchase ... The offering is subject to market and other conditions, and ... the offering may be completed, or as to the actual ...
... wholly owned subsidiary of British company Innovative Carbon Limited today ... 10th April to 13th. , Graphene, a sheet of carbon ... wonder material. First isolated at Manchester University in 2004, ... race has been on to produce it commercially. To ...
Cached Biology Technology:UCF scientists use nanotechnology to hunt for hidden pathogens 2Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants 2Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants 3UK company to demonstrate their commercially effective graphene production process 2
(Date:7/8/2014)... OhioThe future health of the world,s coral reefs and ... on the ability of one tiny symbiotic sea creature ... of algae it cooperates with. , In the first ... University discovered that coralstiny reef-forming animals that live symbiotically ... of heat stress, called "bleaching," when they keep large ...
(Date:7/8/2014)... Think of your next exercise workout as a "fun run" or ... of it as exercise or as a workout and you,ll later ... findings from the Cornell Food and Brand Lab study involved two ... a small lake and were either told it was going to ... the first study, 56 adults completed their walk and were then ...
(Date:7/8/2014)... NY, July 8, 2014Novel oligonucleotide-based drugs in development ... diseases. A group of industry and regulatory scientists ... recommendations for evaluating the pharmacological safety of oligonucleotide ... Acid Therapeutics , a peer-reviewed journal from Mary ... on the Nucleic Acid Therapeutics ...
Breaking Biology News(10 mins):For corals adapting to climate change, it's survival of the fattest -- and most flexible 2For corals adapting to climate change, it's survival of the fattest -- and most flexible 3For corals adapting to climate change, it's survival of the fattest -- and most flexible 4
... issue of G&D report on the discovery of ... The studies from Drs. Alexander Stark and Manolis ... Lai (MSKCC) and colleagues, both reveal that antisense ... the novel miRNA precursor mir-iab-8, which is processed ...
... doctors treating life-threatening emergencies such as allergy attacks may give ... Adrenaline is stored in salt water in glass ampoules ... The amount of adrenaline contained in the ampoule is usually ... per 1 mL of salt water) and a ratio (1 ...
... team at Weill Cornell Medical College in New York City ... production of an immune system cytokine called interleukin-10 (IL-10). ... in a biochemical pathway that,s long been tied to disorders ... AIDS. "IL-10 production has to be kept in a ...
Cached Biology News:Doctors may be giving the wrong dosage of adrenaline in an emergency because of labelling 22 genes are important key to regulating immune response 22 genes are important key to regulating immune response 3